Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: Modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings

Journal of Lipid Mediators and Cell Signalling

Volumn 13, Issue 1, 1996, Pages 1-8

  Terashita, Z I ^a   Imura, Y ^a   Nishikawa, K ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

CV 4151; Isbogrel; PGI2 production; Rabbit platelets; Rat aortic rings; TXA2 synthase inhibition

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; INDOMETACIN; ISBOGREL; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROSTANOID; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RABBIT; RADIOIMMUNOASSAY; RAT; THORACIC AORTA; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

EID: 0030061895     PISSN: 09297855     EISSN: None     Source Type: Journal    
DOI: 10.1016/0929-7855(95)00009-7     Document Type: Article

References (15)

1. J.W. Aiken R.J. Shebuski O.V. Miller R.R. Gorman Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis J. Pharmacol. Exp. Ther. 219 1981 299 308
2. 2 balance: Pathophysiological and therapeutic implications Br. Med. Bull. 39 1983 271 276
3. N.E. Farber G.J. Gross Prostaglandin redirection by thromboxane synthetase inhibition. Attenuation of myocardial stunning in canine heart Circulation 81 1990 369 380
4. 2 analogue, on human blood platelet behavior and vascular contractility Eur. J. Pharmacol. 114 1985 129 137
5. P. Gresele D. Blockmans H. Deckmyn J. Vermylen Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders J. Pharmacol. Exp. Ther. 246 1988 301 307
6. Y. Imura Z. Terashita K. Nishikawa The role of thromboxane (TX) A Z in rabbit arterial thrombosis induced by endothelial damage Thromb. Res. 59 1990 195 205
7. K. Kato S. Ohkawa S. Terao Z. Terashita K. Nishikawa Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of ω-pyridylalkenoic acids J. Med. Chem. 28 1985 287 294
8. T. Kuzuya Y. Kimura S. Hoshida K. Kodama N. Nakamura Y. Hamanaka A. Kitabatake T. Kamada M. Tada The effect of CV-4151, a selective inhibitor of thromboxane synthetase, on prostanoid formation and platelet aggregation in humans Cardiovasc. Drugs Ther. 2 1988 693 700
9. 2 and prostacyclin Pharmacol. Rev. 30 1979 293 331
10. 2 and cardiac functions in the perfused guinea-pig heart Jap. J. Pharmacol. 32 1982 351 358
11. Z. Terashita S. Tsushima Y. Yoshioka H. Nomura K. Nishikawa CV-3988 — a specific antagonist of platelet activating factor (PAF) Life Sci. 32 1983 1975 1982
12. 2 synthetase inhibitor Thromb. Res. 41 1986 223 237
13. Z. Terashita Y. Imura M. Kawamura K. Kato K. Nishikawa Effects of thromboxane AZ synthase inhibitors (CV-4151 and Ozagrel), aspirin and ticlopidine on the thrombosis caused by endothelial cell injury Thromb. Res. 77 1995 411 421
14. 1 and D2 on platelet aggregation in different species Prostaglandins 16 1978 373 388
15. B.J.R. Whittle S. Moncada Pharmacological interactions between prostacyclin and thromboxanes Br. Med. Bull. 39 1983 232 238